CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) will report its 2025 annual financial results and provide a company update after market close on March 3, 2026. A conference call is scheduled for March 3 at 4:30 p.m. ET with a replay available for one year.

The company highlighted its FDA-approved hospital, gastroenterology and oncology portfolio and noted ongoing Phase II trials for ifetroban in systemic sclerosis, DMD cardiomyopathy and idiopathic pulmonary fibrosis.

Key Figures

Earnings release date: March 3, 2026 Conference call time: 4:30 p.m. Eastern Time Replay availability: 1 year

3 metrics

Earnings release date March 3, 2026 Scheduled 2025 annual financial results and company update

Conference call time 4:30 p.m. Eastern Time Timing of March 3, 2026 results call

Replay availability 1 year Duration of access to earnings call replay

Market Reality Check

Price: $3.92 Vol: Volume 67,037 is well bel...

low vol

$3.92 Last Close

Volume Volume 67,037 is well below the 20-day average of 183,204, suggesting limited pre-announcement positioning. low

Technical Shares at $3.87 are trading above the 200-day MA of $3.64, but remain 46.69% below the 52-week high.

Peers on Argus

CPIX was down 1.54% ahead of its earnings-date news, while key peers were mixed:...

1 Up

CPIX was down 1.54% ahead of its earnings-date news, while key peers were mixed: DRRX (-1.04%), RMTI (-3.06%), CRDL (-3.32%), INCR (-3.41%), and ASRT (+2.56%). Momentum scanner only flagged SCYX (+10.36%), indicating stock-specific rather than broad sector-driven action.

Historical Context

5 past events · Latest: 2026-02-04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-02-04	Fast Track designation	Positive	+4.0%	FDA Fast Track Designation for ifetroban in DMD heart disease.
2025-12-08	Reimbursement update	Positive	-9.2%	Caldolor J-code linked to reimbursement price for non-opioid pain management.
2025-11-04	Revenue update	Positive	-3.6%	Reported Q3 and YTD 2025 revenue growth and asset/liability position.
2025-10-28	Earnings date notice	Neutral	-1.5%	Announcement of Q3 2025 results release and conference call timing.
2025-10-20	Portfolio expansion	Positive	+3.5%	Talicia co-commercialization joint venture and long-dated IP protections.

Pattern Detected

Recent CPIX news often produced mixed or negative next-day moves, even on operationally positive updates, indicating a tendency toward price divergence from headline tone.

Recent Company History

Over the last several months, Cumberland reported Q3 2025 revenues of $8.3M and year‑to‑date revenues of $30.8M, reflecting 12% growth versus the prior year’s first nine months. It expanded its portfolio via a Talicia co‑commercialization deal effective Oct 20, 2025 and secured a reimbursement‑linked J‑code for Caldolor on Dec 8, 2025. More recently, oral ifetroban for DMD heart disease received FDA Fast Track designation on Feb 4, 2026. Today’s earnings‑date announcement follows this steady stream of clinical and commercial developments.

Market Pulse Summary

This announcement schedules release of Cumberland’s 2025 annual financial results and a company upda...

Analysis

This announcement schedules release of Cumberland’s 2025 annual financial results and a company update for March 3, 2026, along with a conference call and one‑year replay. It follows prior milestones like FDA Fast Track designation for ifetroban and expansion via Talicia and Caldolor initiatives. Investors may focus on revenue trends, cash levels, and progress in Phase II ifetroban programs as key markers of execution and future optionality.

Key Terms

transdermal system, euvolemic, hypervolemic, hyponatremia, +3 more

7 terms

transdermal system medical

"Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting"

A transdermal system is a medical product, most often a patch, that releases a drug through the skin into the bloodstream over a set period so patients receive steady doses without pills or injections; think of it as a slow‑release sticker that delivers medicine through the skin. For investors it matters because device design, manufacturing, regulatory approval, patent protection and patient convenience all shape market size, recurring revenue and the risk of recalls or legal issues.

euvolemic medical

"euvolemic and hypervolemic hyponatremia;Vibativ® (telavancin) injection"

Euvolemic describes a normal amount of fluid in the body—neither dehydrated nor carrying excess fluid—usually referring to blood and plasma volume. For investors reading clinical or regulatory announcements, noting that patients are euvolemic signals a stable baseline for safety and effectiveness assessments, influencing how drug effects, side effects or dosing are interpreted; think of it as testing a vehicle when its fuel tank is at the expected level.

hypervolemic medical

"euvolemic and hypervolemic hyponatremia;Vibativ® (telavancin) injection"

Hypervolemic describes a medical state in which the body has too much fluid in the bloodstream and tissues, like an overfilled water balloon putting pressure on vessels and organs. For investors, mentions of hypervolemia in clinical reports or corporate disclosures can signal safety issues, higher treatment or hospitalization costs, or complications that affect a drug’s or device’s market prospects and regulatory review.

hyponatremia medical

"euvolemic and hypervolemic hyponatremia;Vibativ® (telavancin) injection"

A condition where the level of sodium in the bloodstream falls below a healthy range, disrupting the body’s fluid balance and affecting brain and nerve function. For investors, hyponatremia matters because it can be a key safety issue in drug trials, a cause of hospital admissions, or a regulatory concern for medical products; like a thermostat gone off balance, it signals potential risks that can affect clinical outcomes, costs, and company value.

Systemic Sclerosis medical

"Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy"

Systemic sclerosis is a chronic autoimmune disease where the body's repair system overreacts, causing hardening and tightening of skin and internal organs much like scar tissue spreading beyond a wound. It matters to investors because it creates a clear medical need for new treatments, influences the size and urgency of clinical trials, and affects regulatory scrutiny, pricing power, and long-term healthcare costs tied to any therapy or diagnostic that proves effective.

Idiopathic Pulmonary Fibrosis medical

"ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis."

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

H. pylori infection medical

"Talicia® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection."

H. pylori infection is an infection of the stomach lining caused by the bacterium Helicobacter pylori that can cause chronic stomach inflammation, ulcers, and raise the long‑term risk of stomach cancer. For investors it matters because diagnosis, treatment, and prevention drive demand for drugs, diagnostics and medical procedures, influence clinical trial outcomes and regulatory decisions, and can affect sales and valuation in healthcare and consumer health businesses — similar to how a persistent pest can change maintenance and replacement needs for a property.

AI-generated analysis. Not financial advice.

NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026.

A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update.

The link to register is https://register-conf.media-server.com/register/BI6effc1a9cae9445f9bb0d60817870ffa.

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically
call them at the start of the conference.

A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/w5m9usns.

Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique
products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.

The company's portfolio of FDA-approved brands includes:

• Acetadote^® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
• Caldolor^® (ibuprofen) injection, for the treatment of pain and fever;
• Kristalose^® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
• Sancuso^® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
• Vaprisol^® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
• Vibativ^® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and
• Talicia^® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection.

The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.

For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at www.cumberlandpharma.com.

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-2025-annual-financial-results--company-update-302696211.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

When will Cumberland Pharmaceuticals (CPIX) release 2025 financial results and host the earnings call?

Cumberland will release its 2025 results after market close on March 3, 2026, with an earnings call at 4:30 p.m. ET. According to the company, a replay will be available for one year via its investor relations page and media-server link.

How can investors join the Cumberland (CPIX) March 3, 2026 conference call?

Investors can register via the provided registration link to receive dial-in and PIN details or use a "Call Me" option at call start. According to the company, registration supplies phone access and automatic call options for participants.

Which FDA-approved products did Cumberland Pharmaceuticals (CPIX) list in the March 2026 announcement?

The company listed approved brands including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia. According to the company, these products target hospital acute care, gastroenterology, and oncology segments.

What clinical development programs did Cumberland (CPIX) mention in the March 3, 2026 update?

Cumberland noted Phase II programs for its ifetroban candidate in systemic sclerosis, Duchenne cardiomyopathy, and idiopathic pulmonary fibrosis. According to the company, these trials are ongoing and focus on those specified indications.

Will the Cumberland (CPIX) earnings call be available after the live event, and for how long?

Yes. A replay of the March 3, 2026 conference call will be available for one year. According to the company, the replay can be accessed on its investor relations site or via the provided media-server replay link.